Cytokine effects on behavior may be related to alterations in glutamate metabolism. We therefore measured glutamate concentrations in brain regions shown to be affected by inflammatory stimuli including the cytokine interferon (IFN)-alpha. IFN-alpha is known to alter neural activity in the dorsal anterior cingulate cortex (dACC) and basal ganglia in association with symptoms of depression and increases in peripheral cytokines including the tumor necrosis factor (TNF) and its soluble receptor. Single-voxel magnetic resonance spectroscopy (MRS) was employed to measure glutamate concentrations normalized to creatine (Glu/Cr) in dACC and basal ganglia of 31 patients with hepatitis C before and after B1 month of either no treatment (n ¼ 14) or treatment with IFN-alpha (n ¼ 17). Depressive symptoms were measured at each visit using the Inventory of Depressive Symptoms-Clinician Rating (IDS-C) and the Multidimensional Fatigue Inventory. IFN-alpha was associated with a significant increase in Glu/Cr in dACC and left basal ganglia. Increases in dACC Glu/Cr were positively correlated with scores on the IDS-C in the group as a whole, but not in either group alone. Glu/Cr increases in left basal ganglia were correlated with decreased motivation in the group as a whole and in IFN-alpha-treated subjects alone. No Glu/Cr changes were found in the right basal ganglia, and no significant correlations were found between Glu/Cr and the inflammatory markers. IFN-alphainduced increases in glutamate in dACC and basal ganglia are consistent with MRS findings in bipolar depression and suggest that inflammatory cytokines may contribute to glutamate alterations in patients with mood disorders and increased inflammation.
INTRODUCTION
Evidence suggests that inflammatory cytokines target cortical and subcortical brain regions that mediate effects of inflammation on behavior. Neuroimaging studies have shown that administration of cytokines or cytokine inducers can alter neural activity in basal ganglia and anterior cingulate cortex (dACC) leading to behavioral changes. For example, using functional magnetic resonance imaging (fMRI), the inflammatory cytokine interferon (IFN)-alpha was found to decrease neural activation in ventral striatum during a reward-processing task, which correlated with reduced motivation (Capuron et al, 2012) . Similar results were found following administration of endotoxin to healthy volunteers, who also exhibited reduced ventral striatal activation during a monetary reward task that correlated with depressed mood . In addition, healthy volunteers exposed to typhoid vaccination (compared with placebo) showed altered activation in the substantia nigra that was associated with reduced psychomotor speed and increased peripheral blood interleukin-6 (Brydon et al, 2008) .
Cytokine effects on the anterior cingulate cortex (ACC) have also been found in the context of exposure to multiple inflammatory stimuli. Increased activation of dorsal ACC (deACC) (Broadman's area (BA) 24) in response to a 'location-detection' visuospatial challenge paradigm was seen during fMRI in hepatitis C patients treated with IFN-alpha compared with controls (Capuron et al, 2005) . In addition, administration of typhoid vaccination was associated with increased dACC activation compared with placebo using a Stroop task in healthy volunteers (Harrison et al, 2009) . Increased secretion of soluble tumor necrosis factor receptor 2 (sTNFR2) during psychosocial stress has also been found to correlate with greater dACC activation in response to social isolation using a cyberball-exclusion paradigm during fMRI (Slavich et al, 2010) . Thus, the basal ganglia and dACC appear to represent important targets of immune activation in multiple paradigms using several distinct immune stimuli, ultimately leading to behavioral changes.
One mechanism that may underlie these cytokine effects on neural activity is altered glutamate metabolism. Increased glutamate neurotransmission is believed to contribute to behavioral alterations in mood disorders, and inflammatory cytokines have been shown to increase synaptic and extrasynaptic concentrations of glutamate by decreasing glutamate transporters and increasing glutamate release from relevant glial elements including astrocytes (Tilleux and Hermans, 2007; Ida et al, 2008; Sanacora et al, 2012) . Of note, IFN-alpha-induced neurotoxicity in the human immunodeficiency virus (HIV) encephalitis mouse model has also been shown to be mediated by increased N-methyl-D-aspartate (NMDA) signaling, presumably secondary to increased glutamate activation of NMDA receptors (Sas et al, 2009) . Moreover, patients with bipolar depression have been reliably found to exhibit increased glutamate in the ACC using magnetic resonance spectroscopy (MRS) and also exhibit postmortem evidence of neuroinflammation including microglial activation (Yuksel and Ongur, 2010; Stertz et al, 2013) . Finally, blockade of NMDA receptors using ketamine has been shown to reverse behavioral changes induced by activation of inflammatory pathways by lipopolysaccharide (Walker et al, 2013) .
To further examine the impact of inflammatory cytokines on glutamate metabolism in the brain, we conducted MRS before and after the 4th dose of IFN-alpha in patients with hepatitis C virus (HCV). We hypothesized that IFN-alpha would increase glutamate concentrations in basal ganglia and dACC as measured by single-voxel proton MRS. Singlevoxel MRS allows detection of a variety of neurometabolite markers, typically in concentrations of 0.5-10 mM within cells or in extracellular spaces, including glutamate (van der Graaf, 2010). MRS glutamate assessments were correlated with changes in behavior as well as changes in the plasma concentration of TNF and sTNFR2, both of which have been associated with IFN-alpha-induced behavioral changes including depression and fatigue (Raison et al, 2009) .
MATERIALS AND METHODS
Thirty-one HCV-positive patients (20 females and 11 males) were enrolled in the study. All subjects were serum positive for HCV-RNA by reverse transcription-PCR. Exclusion criteria were: liver failure; decompensated or advanced cirrhosis (Child-Pugh Score46); liver disease from any cause other than HCV; HIV infection; unstable cardiovascular, endocrinologic, hematologic, renal or neurological disease (as determined by laboratory testing and physical examination); current major depression, substance abuse and/or dependence within the past year; or lifetime history of schizophrenia or bipolar disorder as determined by Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (SCID IV) (First et al, 2002) . Anxiety disorders were not exclusionary. Patients were required to be antidepressant-free for at least 1 year and off all other psychotropic medications for at least 1 month before MRS scanning. Of note, one patient was allowed to participate after taking a sedative/hypnotic the night before the scan. In addition, patients had to be free of contraindications to MRI including metallic implants and claustrophobia.
Study Design
A prospective, longitudinal design was employed. Patients in the IFN-alpha treatment group (n ¼ 17) underwent MRS scans, psychiatric assessments, and blood sampling within 7 days before starting IFN-alpha administration (baseline or visit 1) and within 4-6 days following their fourth IFN-alpha injection (visit 2). A HCV-control group (n ¼ 14) awaiting IFN-alpha, underwent MRS scans, psychiatric ratings, and blood draws at baseline (visit 1) and B1 month later (visit 2), similar to the IFN-alpha treatment group. Mean time from visit 1 to visit 2 was 37.1 SD 12.0 days for IFNalpha-treated subjects and 31.6 SD 6.0 days for controls (t ¼ À 1.55, df ¼ 29, p ¼ 0.13). Assignment to the treatment vs control group and type of IFN-alpha was determined by patients and their physicians and was not controlled by the study protocol. Hepatitis C patients in the IFN-alpha group were treated with either pegylated IFN-alfa-2b (Pegintron, Merck 1.5 mcg/kg/week SC)(n ¼ 1) or pegylated IFN-alfa-2a (Pegasys, Roche 184 mcg/week/kg SC)(n ¼ 16) plus ribavirin (800-1200 mg/d)(n ¼ 17) in the presence or absence of telaprevir (750 mg p.o. t.i.d.)(n ¼ 10) or boceprevir (800 mg p.o. t.i.d.)(n ¼ 1) as determined by their treating physician. Non-fasting blood samples were collected between 1 and 2 pm to reduce circadian variation in inflammatory mediators, although previous studies by our group have not found circadian variations in TNF or sTNFR2 in this patient population (unpublished observations). All study procedures were approved a priori by the Emory University institutional review board, and all subjects provided written informed consent.
Behavioral Assessments
Depression was evaluated by the Inventory for Depressive Symptomatology-Clinician Rating (IDS-C); a 30-item scale that provides valid and reliable ratings of severity of depressive symptoms, including depressed mood, guilt, suicidal ideation, sleep, appetite, energy, libido, and concentration (Trivedi et al, 2004) . Clinician ratings were not blinded to group assignment, as it is difficult to mask the profound behavioral effects of IFN-alpha.
To evaluate severity of fatigue, subjects completed the self-rated 20-item Multidimensional Fatigue Inventory (MFI-20) (Smets et al, 1995) . The MFI assesses five dimensions of fatigue known to be common among medically ill patients including general fatigue, physical fatigue, mental fatigue, reduced activity, and reduced motivation (Stein et al, 2004) .
Plasma Inflammatory Cytokines
Plasma was isolated from centrifuged whole blood collected in chilled EDTA tubes. Samples were stored at À 80 1C for the batched assay. Plasma TNF and sTNFR2 were measured by quantitative enzyme-linked immunosorbent assays (R & D Systems, Minneapolis, MN). Assays were performed according to manufacturer's specifications and were run in IFN-alpha-induced glutamate increaseduplicate. Inter-and intra-assay variability were reliably o12% for TNF and o10% for sTNFR2. Lower limits of detection for TNF and sTNFR2 were 0.19 pg/ml and 2.3 ng/ml, respectively. All biological samples were analyzed by research staff blinded to the clinical status of study participants, and no samples were below the limit of detection.
Neuroimaging Protocol
MRS acquisition and processing. The scanning protocol and post-processing methodology have been previously reported (Ajilore et al, 2005; Ajilore et al, 2007; Haroon et al, 2009) . Briefly, all images were acquired using a Siemens 3 (Figure 1 ). The spatial localization was implemented using point resolved spectroscopy (PRESS) pulses (Bottomley, 1987) . The dACC voxel was always acquired before left and right basal ganglia voxels in the same order. Water suppression was achieved with the help of chemical shift-selective (CHESS) pulses. Numerically optimized Shinnar-Le Roux radio frequency pulses were used for PRESS (901, 1801, 1801) and CHESS (901, 901, 901) (Haase et al, 1985) . The parameters used for spectral acquisition were TR ¼ 3000 ms, TE ¼ 30 ms, sampling size ¼ 1024, 128 averages. Four unsuppressed water free induction decay spectra were also acquired for eddy current suppression and phase correction (Klose, 1990) . The scan was acquired using a bandwidth of 2000 Hz and using 2048 complex data points. The FWHM of the unsuppressed water peak was optimized to o14 Hz.
MRS post-processing. The raw files were processed using LC Model package-Version 6-2-2b (Provencher, 2012) . The LC Model is an operator-independent commercial software package that fits in vivo metabolite spectra using model resonances acquired under comparable scanning conditions from multiple compounds in standard phantom solutions. The water-suppressed time-domain data were analyzed between 1.0 p.p.m. and 4.0 p.p.m. without further T1 and T2 corrections. The basis set provided by the vendor of the LC Model (http://s-provencher.com/pages/lcm-applications. shtml) was used and then scaled to consistent receiver gain. It should be noted that the 6-2-2b version of LC Model when used with a short TE (o30 ms) sequence in high field strength (3T) can be scaled to provide relatively accurate estimates of glutamate (Glu). Nevertheless, as recommended by the vendor, concentrations and ratios with Cramer-Rao lower bounds (CRLB) 420% were not used for analysis. The CRLB for glutamate (Glu) was reliably o10%, indicating low metabolite variance and good fit. Of note, glutamine resonances were fit poorly with CRLB (420%) and hence were not used in the analysis. Water was used as the internal reference, and creatine þ phosphocreatine (Cr) was used to scale the data to model spectra across subjects (per LC Model Manual) and to minimize intra-and inter-individual variation. No significant differences in Cr concentrations were seen between IFN-alpha and control groups in any of the voxels at visit 1 or visit 2, and no significant differences in Cr were seen between visit 1 and visit 2 for either group. All analyses used the Glu/Cr ratio and were conducted by investigators blinded to group assignment.
Statistical Analysis
Student's t-tests and Fisher's exact tests, where appropriate, were used to compare groups in socio-demographic and Figure 1 Placement of MRS voxels and representative spectrum: MRS voxels were placed as indicated: a 2 Â 3 Â 1-cm 3 voxel in the dorsal anterior cingulate region (dACC)(BA24) and two 1.7 Â 3 Â 1.7-cm 3 voxels in the left and right basal ganglia. A representative spectrum from the dACC is depicted.
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clinical variables at baseline. To examine main effects of group and time and their interaction for relevant dependent variables (eg behavior, Glu/Cr, and cytokines), repeated measures analysis of variance was used. Bonferroni post hoc tests were used to compare specific means of interest. Delta values for the dependent measures were calculated by subtracting visit 1 from visit 2 and compared using Student's t-test. Delta values were also used to explore correlations between relevant dependent measures using Spearman coefficients for non-normally distributed data. Bonferroni correction was used to control for multiple comparisons where indicated. To control for relevant demographic and clinical covariates, partial correlation coefficients were employed. All statistical computations were performed using IBM-SPSS (International Business Machines, New York, NY). Of note, owing to poor scan quality, there was missing data for the following: dACC: one IFN-alpha-treated subject at visit 1; left basal ganglia: 2 IFNalpha-treated subjects (both visit 1); right basal ganglia: 1 control subject at visit 1 and 2 treatment patients (both visit 2). Subjects were excluded from analyses only for brain regions where imaging data was missing.
RESULTS
Of 46 subjects who signed informed consent, 31 (17 IFNalpha-treated patients and 14 HCV controls) met entry criteria and were enrolled in the study. Excluded patients did not differ significantly from the study group on any of the socio-demographic or clinical variables (data not shown). No significant differences between IFN-alphatreated patients and controls were found with regard to age, sex, race, BMI, education, employment status, and history of substance abuse or depression, although there was a trend for a higher BMI (p ¼ 0.06) and a numerically higher number of males (p ¼ 0.14) in the IFN-alpha treatment group (Table 1) .
Behavioral Symptoms
A significant main effect of time and a group-by-time interaction was found for depressive symptom severity as measured by the IDS-C (F(1,29) ¼ 27.03, po0.001 and F(1,29) ¼ 17.90, po0.001, respectively) with IFN-alphatreated patients exhibiting significant increases in depression severity from visit 1 to visit 2 compared with controls ( Figure 2) . No main effects of group or time or group-by-time interaction were found for Glu/Cr in the right basal ganglia.
Inflammatory Cytokines
As previously reported, there was a significant groupby-time interaction for plasma TNF (F(1,29) ¼ 4.84, p ¼ 0.036) and a main effect of time and a group-bytime interaction for sTNFR2 (F(1,29) ¼ 18.59, po0.001 and F(1,29) ¼ 9.81, po0.005, respectively) with significant increases in both inflammatory mediators in IFN-alphatreated patients from visit 1 to visit 2 compared with controls (Table 2) . 
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Correlations Glu/Cr and behavioral assessments. Correlations were assessed between delta Glu/Cr in dACC and left basal ganglia and delta depression severity and fatigue correcting for multiple comparisons (2 brain regions Â 6 behavioral endpoints ¼ 12 comparisons). Delta Glu/Cr in the dACC in the group as a whole was significantly correlated with delta depression severity (IDS-C)(r s ¼ 0.54, df ¼ 28, p ¼ 0.002, p corr ¼ 0.024) but was not significantly correlated with delta fatigue subscale scores (Figure 3 ). Splitting the groups into IFN-alpha-treated and HCV controls revealed no significant correlations between delta Glu/Cr and IDS-C in either group alone, suggesting a correlation largely driven by the differences in Glu/Cr and IDS-C between groups. In contrast, delta Glu/Cr in left basal ganglia in the group as a whole was significantly correlated with the delta MFI subscale for reduced motivation (r s ¼ 0.60, df ¼ 27, p ¼ 0.001, p corr ¼ 0.012). No other significant correlations for left basal ganglia and behavioral endpoints were found. Splitting the groups into IFN-alpha-treated subjects and HCV controls revealed that delta Glu/Cr in left basal ganglia was significantly correlated with reduced motivation 
(r s ¼ 0.68, df ¼ 13, p ¼ 0.006) in IFN-alpha-treated patients alone but not in HCV controls (r s ¼ 0.42, df ¼ 12, p ¼ 0.14) (  Figure 3 ). The significant correlation between delta Glu/Cr in the left basal ganglia and delta-reduced motivation in IFN-alpha-treated patients persisted after controlling for age, sex, race, and BMI (po0.05).
Glu/Cr and inflammatory markers. Correlations were assessed between delta Glu/Cr in dACC and left basal ganglia with delta plasma TNF markers correcting for multiple comparisons (2 brain regions and 2 inflammatory markers ¼ 4 comparisons). Delta sTNFR2 was significantly correlated with delta Glu/Cr in dACC (r s ¼ 0.43, n ¼ 28, 
DISCUSSION
The data presented herein demonstrate significant increases in glutamate as measured by the Glu/Cr ratio using MRS in brain regions known to be targets of cytokine-induced behavioral changes including the dACC and left basal ganglia (Miller et al, 2013) . Moreover, consistent with our previous work on the effects of IFN-alpha on neural activity in the ventral striatum and motivation (Capuron et al, 2012) , increases in Glu/Cr ratios in left basal ganglia significantly correlated with reduced motivation. Taken together, these data suggest that effects of inflammatory cytokines on the brain may be mediated in part by increased glutamate. Under physiological conditions, the glutamate signal as measured by MRS is believed to be primarily derived from the intracellular compartment, which contains millimolar concentrations of glutamate as opposed to the extracellular compartment that contains concentrations in the nanomolar range, well below the detection limits of the MRS procedures employed in this and other studies (Mark et al, 2001; Potter et al, 2013) . In part, related to its potential role in excitotoxicity, extracellular glutamate is maintained at these low concentrations by a family of excitatory amino-acid transporters (EAATs), which are located on the surface of astrocytes and oligodendrocytes and use a high-energy reuptake process to overcome the 1000-fold concentration gradient between intracellular and extracellular compartments (Schousboe and Waagepetersen, 2005; Tilleux and Hermans, 2007; Niciu et al, 2012) . Under pathophysiologic conditions, however, glutamate concentrations in the extracellular space may significantly increase as a result of disruption in EAAT expression and/or function as well as alterations in glutamate metabolism. Relevant to the current findings, inflammatory cytokines including TNF have been shown in multiple studies to decrease the expression and function of EAATs. In addition, inflammatory cytokines can lead to reverse efflux of glutamate from astrocytes (Mark et al, 2001; Jourdain et al, 2007) and decrease the activity of glutamate metabolizing enzymes such as glutamine synthetase (Choudary et al, 2005) . All of these changes can result in elevated extracellular glutamate concentrations as observed in this study with attendant consequences on neuronal integrity.
Consistent with the impact of inflammatory cytokines on glutamate metabolism, a number of brain disorders associated with neuroinflammation including brain trauma, multiple sclerosis, stroke, neurodegenerative disorders such as Huntington's disease, Alzheimer's disease, and infectious diseases such as HIV have been reported to be associated with increased glutamate as measured by MRS (Mark et al, 2001; Lee et al, 2003; Srinivasan et al, 2005; Mehta et al, 2013) . Although it has been assumed that the increased glutamate in these disorders as well as those reported herein reflect an increase in the extracellular glutamate pool, Figure 3 Correlations between changes in behavior and Glu/Cr in control and IFN-alpha-treated subjects. (a) Change in depression scores (delta IDS-C) from visit 1 (baseline) to visit 2 (after the 4th dose of IFNalpha) were correlated in the total sample of 31 IFN-alpha-treated (n ¼ 17) and untreated (n ¼ 14) subjects with changes in glutamate concentrations normalized to creatine (delta Glu/Cr) in the dorsal anterior cingulate cortex (dACC)(Spearman r ¼ 0.54, df ¼ 28, p ¼ 0.002, p corr ¼ 0.024). Of note, no significant correlations were found between dACC Glu/Cr and IDS-C in the groups individually. (b) Change in motivation scores (delta reduced motivation on the MFI) was significantly correlated with delta Glu/Cr in the left basal ganglia (r s ¼ .60, df ¼ 27, p ¼ 0.001, p corr ¼ 0.012) in the group as a whole and in IFN-alpha-treated patients only (r s ¼ 0.68, df ¼ 13, p ¼ 0.006).
IFN-alpha-induced glutamate increase E Haroon et al without more definitive assessments, this conclusion cannot be verified (Mark et al, 2001 ). An additional mechanism that may contribute to increased extracellular glutamate in IFN-alpha-treated patients is the kynurenine pathway. IFN-alpha as well as other inflammatory cytokines have been shown to stimulate the production of kynurenine that can be converted in the brain by microglia into quinolinic acid, which has been associated with IFN-alpha-induced depression (Walker et al, 2013) . Quinolinic acid has been shown to stimulate synaptosomal glutamate release and block glutamate reuptake in astrocytes in vitro and stimulate glutamate release in rats in vivo (Tavares et al, 2002) . Interestingly, increased quinolinic acid immunoreactive cells have been found in the same ACC region sampled in the current study (Steiner et al, 2011) . Finally, ketamine, an antagonist at the NMDA receptor, has been shown to reverse depressive symptoms induced by the inflammatory stimulus, lipopolysaccharide, which has been shown to increase CNS quinolinic acid (Walker et al, 2013) .
The data from IFN-alpha-treated patients are consistent with findings from patients with bipolar disorder where elevated glutamate concentrations in several ACC regions as well as the basal ganglia have been reported using MRS. Of relevance to inflammation, considerable data have documented increased peripheral blood inflammatory cytokines in bipolar patients as well as increased microglial activation and cytokine expression in the brain in postmortem samples. (Soczynska et al, 2009; Yuksel and Ongur, 2010; Leboyer et al, 2012) . Unfortunately, however, correlations among glutamate concentrations, behavior, and inflammatory markers have not been conducted (or reported) in bipolar disorder.
The findings from this study contrast with recent results reporting no glutamate changes in a MRS voxel situated on the pregenual ACC in HCV patients undergoing IFN-alpha therapy (Taylor et al, 2013) . Differences in study design involve our inclusion of a non-IFN-alpha-treated control group as well as our use of the traditional PRESS technique to assess glutamate concentrations as opposed to the 'SPECIAL' technique used to assess glutamate concentrations in the other study. Moreover, there can be considerable overlap between glutamate and glutamine signals, which may account for several glutamate/glutamine inconsistencies in the literature (Yuksel and Ongur, 2010) . In a related fashion, the decreased rate of 13 C incorporation into the intracellular pool of glutamate and glutamine (reflected by decreased 13 C glutamate and 13 C glutamine as measured by MRS) following chronic unpredictable stress (CUS) in rats may represent cytokine-induced effects on glutamate reuptake and release leading to increased extracellular glutamate (Banasr et al, 2010) . Indeed, behavioral effects of the CUS in mice have been shown to be mediated in part by inflammatory cytokines (Koo and Duman, 2008) .
It should be mentioned that the mechanisms by which increased glutamate occurs in the basal ganglia and dACC may involve different processes. IFN-alpha has been associated with evidence of decreased dopamine similar to Parkinson's disease (PD) (Capuron et al, 2012) . Thus, in addition to the direct effects of cytokines on glutamate metabolism, decreased availability of dopamine may indirectly lead to an overactivation of glutamatergic projections to the striatum and basal ganglia output nuclei as seen in PD (Hallett and Standaert, 2004; Paoletti et al, 2013) . Indeed, D1 receptors in the direct pathway stimulate the release of GABA in the basal ganglia, whereas D2 receptors inhibit glutamate release in the indirect pathway. Depletion of dopamine would therefore be expected to decrease GABAergic inhibitory tone while at the same time increasing glutamatergic output. In contrast, the mechanism of glutamate increase in the dACC may be primarily related to direct effects of inflammatory cytokines on glutamate reuptake and release.
There are several strengths and weaknesses of the study that warrant consideration. We used a standard dose of an immune stimulus administered to medically stable patients off psychotropic medications without substance abuse and compared them with a control population. Limitations include the lack of randomization and blinding of behavioral ratings and the relatively short interval (1 month) between visits 1 and 2, which may have missed more chronic behavioral and neuroimaging changes. In addition, given the small sample size, there is insufficient data to conclusively determine the impact of hemispheric laterality on delta Glu/Cr in the basal ganglia. There is a paucity of data on laterality of glutamate alterations in mood or inflammatory disorders (especially in basal ganglia). The relationship between laterality and depressive symptoms in patients with lesions of the basal ganglia has also been inconclusive, although several studies have supported a relationship between left basal ganglia lesions and depression following stroke and traumatic brain injury (Starkstein et al, 1988; Jorge et al, 1993; Paradiso et al, 2013) . The absence of a non-HCV-infected control group as well as the combination of ribavirin, telaprevir, or boceprevir with IFN-alpha is also a limitation. However, previous work by our group and others has shown that IFNalpha effects on basal ganglia and dACC in HCV-infected patients mirror those seen in non-HCV-infected subjects treated with IFN-alpha alone including patients with cancer and non-human primates as well as healthy volunteers administered other inflammatory stimuli including typhoid vaccination and endotoxin (Miller et al, 2013) .
CONCLUSIONS
This study provides support for the hypothesis that brain regions preferentially targeted by cytokines appear to show elevations in glutamate concentrations that correlate with IFN-alpha-induced behavioral changes notably reduced motivation. Future studies using glutamate antagonists may be relevant in patients with chronic exposure to inflammatory cytokines including patients with mood disorders with increased inflammatory biomarkers.
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